Home>Congress>Celegene settles another lawsuit

Republican Bob Hugin, left, debates Democrat Bob Menendez in the race for New Jersey's U.S. Senate seat on October 24, 2018 in Newark (YOUTUBE)

Celegene settles another lawsuit

NJ drugmaker has now spent $117 million settling cases in 8 days

By David Wildstein, July 31 2019 6:28 pm

Click play for audio version of this story

Celgene has settled a second lawsuit in eight days and will pay $62 million to a company that said they prevented generic versions of Revlimid and Thalomid from entering the market.

The Summit-based pharmaceutical company was headed by Bob Hugin, who spent $36 million of his own money as a candidate for the United States Senate last year.  The cost of life-saving cancer drugs marketed by Celgene helped incumbent Bob Menendez score a 56%-43% victory over Hugin,

Celgene has now agreed to pay Mylan, a Dutch manufacturer of generic drugs, for stifling their ability to create a less expensive version of the cancer drugs.

Last week, Celgene settled a class action lawsuit for $55 million.  The suit alleged that Celgene’s business practices cost cancer patients millions of dollars after Celgene hogged the market for Revlimid and Thalomid, creating higher prices for cancer patients and their insurance companies.

Menendez said the settlement was evidence that Hugin “ lined his own pockets with millions of dollars from long-suffering cancer patients.”

David Mitchell, a cancer patient who uses Revlimid, was a plaintiff in the class action suit.  He founded Patients for Affordable Drugs Action, which spent nearly $3 million on TV ads bashing Hugin’s tenure at Celgene.

“Celgene has abused cancer patients and taxpayers for years,” Mitchell said.  “I only wish there was more we could do to get justice.”

Spread the news:
RELATED ARTICLES
Filter by
Post Page
Highlight National Articles Congress
Sort by

Celegene sale faces some opposition

March 1, 2019 8:58 am

10

Pezzullo backs Hugin

February 13, 2018 12:26 pm

8

Hugin set to announce on Tuesday

February 11, 2018 7:50 pm

8

Leave a Reply

Your email address will not be published. Required fields are marked *